General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KMYKL
ADC Name
RC88-Py-MAA-Val-Cit-PAB-MMAD
Synonyms
RC88-Py-MAA-Val-Cit-PAB-MMAD
   Click to Show/Hide
Organization
REMEGEN, LTD.
Drug Status
Investigative
Structure
Antibody Name
RC88
 Antibody Info 
Antigen Name
Mesothelin (MSLN)
 Antigen Info 
Payload Name
Monomethyl auristatin D
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
PY-MAA-Val-Cit-PABC
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Py-MAA-Val-Cit-PAB-MMAD
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.043&#1770.011
nM
CVCL_0465
High grade ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.043&#1770.011 nM Positive MSLN expression (MSLN+++/++)
Method Description
Oval-Citar-3-MSLN cells with good growth state were added to 96-well cell culture plates (5×104 cells /mL, 100uL/ well) and incubated overnight in a CO2 incubator at 38°C.
In Vitro Model High grade ovarian serous adenocarcinoma Oval-Citar-3-MSLN cells CVCL_0465
References
Ref 1 Anti-mesothelin antibody and antibody drug conjugate thereof